48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial

Shranjeno v:
Bibliografske podrobnosti
izdano v:BMC Infect Dis
Main Authors: Yazdanpanah, Y, Khuong-Josses, M-A, Hocqueloux, L, Pialoux, G, Durant, J, Wynne, B, Granier, C, Tebas, P, Pappa, K, Min, S
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2014
Teme:
Poster Presentation
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4221003/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2334-14-S2-P72
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki